SCHEMBL15445211

SCHEMBL15445211

CC(C)c1ccc2c(c1)N(C)CC2

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
XIAP P98170 1/20 0.42
BIRC2 Q13490 1/20 0.42
NOTUM Q6P988 1/20 0.41
HTR2A P28223 5/20 0.36
HTR2C P28335 5/20 0.36
HTR2B P41595 4/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
NFKB1 P19838 1/20 0.36
HIF1A Q16665 1/20 0.36
ALDH1A1 P00352 2/20 0.36
HTT P42858 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
PDK1 Q15118 1/20 0.35
PDK2 Q15119 1/20 0.35
PDK3 Q15120 1/20 0.35
PDK4 Q16654 1/20 0.35
RORC P51449 1/20 0.34
LMNA P02545 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13252969 0.89 ALDH1A1 (0.44) XIAPBIRC2NOTUMALDH1A1HTT
SCHEMBL26700310 0.88 ALDH1A1 (0.40) XIAPBIRC2NOTUMCYP3A4ALDH1A1
SCHEMBL7919701 0.85 HTR2A (0.43) NOTUMHTR2AHTR2CCYP1A2CYP3A4
SCHEMBL25450201 0.83 LMNA (0.38) XIAPBIRC2HTR2AHTR2CALDH1A1
SCHEMBL19340748 0.80 XIAP (0.44) XIAPBIRC2NOTUMHTR2AHTR2C
SCHEMBL10092725 0.80 XIAP (0.41) XIAPBIRC2NOTUMHTR2AHTR2C
SCHEMBL22685629 0.80 XIAP (0.41) XIAPBIRC2HTR2AHTR2CHTR2B
SCHEMBL22685105 0.80 XIAP (0.41) XIAPBIRC2HTR2AHTR2CHTR2B
SCHEMBL12376502 0.79 LMNA (0.38) NOTUMHIF1AALDH1A1HTTSMN1; SMN2
SCHEMBL15341901 0.78 NOTUM (0.43) XIAPBIRC2NOTUMHTR2AHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230348452-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-11-02 US disclosed
US-20230348452-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-11-02 US disclosed
US-20230192645-A1 INDOLE CARBOXAMIDE COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2023-06-22 US disclosed
US-20230060334-A1 COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 C4 THERAPEUTICS, INC. (US) 2023-03-02 US disclosed
US-11584748-B2 Spirocyclic compounds C4 THERAPEUTICS, INC. (US) 2023-02-21 US disclosed
EP-3265445-B1 LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF PHARMAKEA INC (US) 2021-05-05 EP disclosed
US-10822377-B2 Substituted urea depsipeptide analogs as activators of the ClpP endopeptidase ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) 2020-11-03 US disclosed
WO-2020132597-A1 COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF Revolution Medicines, Inc. (US) 2020-06-25 WO disclosed
US-20200197391-A1 COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF Revolution Medicines, Inc. 2020-06-25 US disclosed
US-20200031872-A1 Substituted Urea Depsipeptide Analogs as Activators of the CLPP Endopeptidase ST. JUDE CHILDREN'S RESEARCH HOSPITAL 2020-01-30 US disclosed
US-9920031-B2 Indole carboxamide compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2018-03-20 US disclosed
US-9802915-B2 Indole carboxamide compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2017-10-31 US disclosed
US-20170260160-A1 INDOLE CARBOXAMIDE COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2017-09-14 US disclosed
US-9688629-B2 Indole carboxamide compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2017-06-27 US disclosed
US-9663520-B2 Bicyclic bromodomain inhibitors ZENITH EPIGENETICS LTD. (CA) 2017-05-30 US disclosed
US-20170066740-A1 INDOLE CARBOXAMIDE COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2017-03-09 US disclosed
US-20160115126-A1 INDOLE CARBOXAMIDE COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY 2016-04-28 US disclosed
US-8778929-B2 Substituted heteroaryl inhibitors of B-RAF BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-07-15 US disclosed
US-8637549-B2 Pyridons as PDK1 inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-01-28 US disclosed
US-20110312939-A1 NEW CHEMICAL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230060334-A1 COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 BRD9, BRD1, BRWD1 XIAP 420/4885BIRC2 347/4885NOTUM 3573/4885
US-20110312939-A1 NEW CHEMICAL COMPOUNDS CCNA1, CCNT1, MKI67 XIAP 837/4885BIRC2 3894/4885NOTUM 4461/4885
US-20230192645-A1 INDOLE CARBOXAMIDE COMPOUNDS BTK, JAK2, BRD4 XIAP 2013/4885BIRC2 1144/4885NOTUM 3479/4885
US-20200197391-A1 COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF KRAS, NRAS, HRAS XIAP 67/4885BIRC2 144/4885NOTUM 4347/4885
US-10822377-B2 Substituted urea depsipeptide analogs as activators of the ClpP endopeptidase CLPP, DNPEP, PEPD XIAP 399/4885BIRC2 1519/4885NOTUM 1085/4885
US-20170066740-A1 INDOLE CARBOXAMIDE COMPOUNDS BTK, JAK2, BRD4 XIAP 2013/4885BIRC2 1144/4885NOTUM 3479/4885
US-20170260160-A1 INDOLE CARBOXAMIDE COMPOUNDS BTK, JAK2, BRD4 XIAP 2013/4885BIRC2 1144/4885NOTUM 3479/4885
US-20230348452-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, BRCA1 XIAP 591/4885BIRC2 1231/4885NOTUM 3778/4885
US-20160115126-A1 INDOLE CARBOXAMIDE COMPOUNDS BTK, JAK2, BRD4 XIAP 2013/4885BIRC2 1144/4885NOTUM 3479/4885
US-11584748-B2 Spirocyclic compounds CRBN, RBX1, XIAP XIAP 3/4885BIRC2 67/4885NOTUM 3896/4885
US-20200031872-A1 Substituted Urea Depsipeptide Analogs as Activators of the CLPP Endopeptidase CLPP, DNPEP, PEPD XIAP 399/4885BIRC2 1519/4885NOTUM 1085/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.